CHRDL1 expression stratified the Taylor (N = 150; 27 metastatic tumors) dataset into two groups with a significant, 438-day difference in overall disease-free survival (relapse; Cox P = 0.0062, absolute hazard ratio (HR) = 2.5). The gene discussed is CHRDL1; the disease is metastatic neoplasm.